Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma
Alessandro Rizzo, Giovanni Brandi
Cancer Treatment and Research Communications (2021) Vol. 27, pp. 100328-100328
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review
Teklie Mengie Ayele, Zelalem Tilahun Muche, Awgichew Behaile Teklemariam, et al.
Journal of Inflammation Research (2022) Vol. Volume 15, pp. 1349-1364
Open Access | Times Cited: 124
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 549-555
Closed Access | Times Cited: 111
Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
Jianming Shen, Hui Shen, Lixin Ke, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 103
Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Alessandro Rizzo, Antonio Cusmai, Francesco Giovannelli, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1404-1404
Open Access | Times Cited: 92
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2022) Vol. 16, Iss. 4, pp. 333-339
Closed Access | Times Cited: 79
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 96
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
Liansha Tang, Jialing Wang, Nan Lin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 92
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 415-423
Closed Access | Times Cited: 91
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta‐Caldarola, et al.
Expert Review of Gastroenterology & Hepatology (2021) Vol. 15, Iss. 11, pp. 1245-1251
Closed Access | Times Cited: 81
Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
Paula Dobosz, Maria Stępień, Anna Golke, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2847-2847
Open Access | Times Cited: 61
Activation of Piezo1 contributes to matrix stiffness‐induced angiogenesis in hepatocellular carcinoma
Miao Li, Xi Zhang, Mimi Wang, et al.
Cancer Communications (2022) Vol. 42, Iss. 11, pp. 1162-1184
Open Access | Times Cited: 59
The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis
Biao Ning, Yixin Liu, Miao Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 55
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, et al.
Future Oncology (2022) Vol. 18, Iss. 18, pp. 2301-2309
Closed Access | Times Cited: 50
Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook
Yinjie Fan, Hang Xue, Hua‐chuan Zheng
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 233-263
Open Access | Times Cited: 43
Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
Shuxian Pan, Zibing Wang
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
Shuo Xu, Ruixue Lai, Qian Zhao, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 52
SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma
Weiqiang You, Jia Ke, Yufeng Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Taobi Huang, Xia Chen, Huiyun Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 34
Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
Betül Gök Yavuz, Elshad Hasanov, Sunyoung S. Lee, et al.
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1195-1207
Open Access | Times Cited: 32
Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
Alessandro Rizzo, Angela Dalia Ricci
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11363-11363
Open Access | Times Cited: 27
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Chang‐Shen Lin, Yu‐Tzu Chang, Zhen-Yang Hong, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3238-3238
Open Access | Times Cited: 25
Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma
Gohar Manzar, Brian De, Chike O. Abana, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1901-1901
Open Access | Times Cited: 25
Biomarkers for response to immunotherapy in hepatobiliary malignancies
Zhifei Lin, Lun‐Xiu Qin, Jinhong Chen
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 413-419
Closed Access | Times Cited: 23
Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6664-6664
Open Access | Times Cited: 22
New Era of Immune-Based Therapy in Intrahepatic Cholangiocarcinoma
Etsushi Kawamura, Tsutomu Matsubara, Norifumi Kawada
Cancers (2023) Vol. 15, Iss. 15, pp. 3993-3993
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top